Adaptimmune Historical Cash Flow
| ADAP Stock | USD 0.73 0.05 7.35% |
Analysis of Adaptimmune Therapeutics cash flow over time is an excellent tool to project Adaptimmune Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 10.7 M or Begin Period Cash Flow of 91.3 M as it is a great indicator of Adaptimmune Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Adaptimmune Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Adaptimmune Therapeutics is a good buy for the upcoming year.
Adaptimmune |
About Adaptimmune Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Adaptimmune balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Adaptimmune's non-liquid assets can be easily converted into cash.
Adaptimmune Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Depreciation
Depreciation indicates how much of Adaptimmune Therapeutics value has been used up. For tax purposes Adaptimmune Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Adaptimmune Therapeutics Plc must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Capital Expenditures
Capital Expenditures are funds used by Adaptimmune Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Adaptimmune Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Exchange Rate Changes
The impact of changes in foreign exchange rates on a company's financial position and results.Most accounts from Adaptimmune Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Adaptimmune Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Adaptimmune Therapeutics' Other Cashflows From Financing Activities is relatively stable compared to the past year. As of 11/28/2024, Capital Expenditures is likely to grow to about 9.5 M, though Free Cash Flow is likely to grow to (138.5 M).
| 2023 | 2024 (projected) | Issuance Of Capital Stock | 624K | 592.8K | Exchange Rate Changes | 3.8M | 3.1M |
Adaptimmune Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Adaptimmune Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adaptimmune Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (17.6M) | 6.6M | 90.2M | (42.1M) | 37.4M | 24.0M | |
| Stock Based Compensation | 11.1M | 10.4M | 20.6M | 18.2M | 11.8M | 10.7M | |
| Free Cash Flow | (115.6M) | (56.5M) | 1.9M | (171.5M) | (145.8M) | (138.5M) | |
| Change In Working Capital | 4.7M | 56.0M | 134.6M | (1.5M) | (25.0M) | (23.8M) | |
| Begin Period Cash Flow | 72.5M | 54.9M | 61.5M | 151.7M | 109.6M | 91.3M | |
| Other Cashflows From Financing Activities | (1.5K) | 5.7M | 759K | 50K | 256K | 268.8K | |
| Depreciation | 8.0M | 7.6M | 6.6M | 6.1M | 9.5M | 5.1M | |
| Other Non Cash Items | (185K) | (55K) | 1.2M | 903K | (23.2M) | (22.0M) | |
| Capital Expenditures | 3.1M | 2.9M | 8.8M | 29.7M | 4.9M | 9.5M | |
| Total Cash From Operating Activities | (112.5M) | (53.6M) | 10.7M | (141.8M) | (140.9M) | (133.8M) | |
| Net Income | (137.2M) | (130.1M) | (158.1M) | (165.5M) | (113.9M) | (119.6M) | |
| Total Cash From Financing Activities | 366K | 340.1M | 3.3M | 12.9M | 880K | 836K | |
| End Period Cash Flow | 54.9M | 61.5M | 151.7M | 109.6M | 147.0M | 124.3M | |
| Sale Purchase Of Stock | 102.7M | 366K | 340.1M | 3.3M | 3.8M | 3.6M | |
| Investments | 98.0M | (276.0M) | 84.6M | 89.1M | 176.5M | 185.4M | |
| Total Cashflows From Investing Activities | 94.9M | (278.9M) | 75.8M | 89.1M | 102.5M | 107.6M | |
| Change To Account Receivables | (1.4M) | 1.8M | (19.4M) | (9.8M) | (1.3M) | (1.4M) | |
| Change To Operating Activities | 2.1M | 742K | (1.5M) | 2.5M | 2.8M | 3.0M | |
| Change To Netincome | 11.9M | 9.0M | 22.3M | 19.1M | 22.0M | 12.8M | |
| Change To Liabilities | 7.6M | 3.9M | 4.2M | 8.3M | 7.5M | 5.2M | |
| Other Cashflows From Investing Activities | (798K) | (1.5M) | (565K) | (207K) | (186.3K) | (177.0K) | |
| Cash And Cash Equivalents Changes | (15.8M) | (17.2M) | 7.5M | 89.8M | 103.3M | 108.5M | |
| Cash Flows Other Operating | (42.9M) | 4.7M | 56.0M | 135.7M | 156.1M | 163.9M |
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
| 0.89 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.76 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.88 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Adaptimmune Stock
| 0.83 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.73 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.59 | PHVS | Pharvaris BV | PairCorr |
| 0.48 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.46 | PMVP | Pmv Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.